MediWound (NASDAQ:MDWD – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare MediWound to similar businesses based on the strength of its valuation, profitability, analyst recommendations, dividends, earnings, risk and institutional ownership.
Analyst Ratings
This is a summary of current ratings for MediWound and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediWound | 1 | 0 | 4 | 0 | 2.60 |
| MediWound Competitors | 9941 | 15330 | 45747 | 1605 | 2.54 |
MediWound presently has a consensus price target of $33.00, suggesting a potential upside of 136.66%. As a group, “Biotechnology” companies have a potential upside of 131.27%. Given MediWound’s stronger consensus rating and higher possible upside, analysts clearly believe MediWound is more favorable than its peers.
Institutional & Insider Ownership
46.8% of MediWound shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 9.2% of MediWound shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares MediWound and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediWound | -234.98% | -61.68% | -30.98% |
| MediWound Competitors | -12,224.75% | -204.85% | -31.52% |
Earnings and Valuation
This table compares MediWound and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| MediWound | $16.96 million | -$23.88 million | -6.31 |
| MediWound Competitors | $688.58 million | $7.69 million | -18.48 |
MediWound’s peers have higher revenue and earnings than MediWound. MediWound is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
MediWound has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500. Comparatively, MediWound’s peers have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.
Summary
MediWound beats its peers on 8 of the 13 factors compared.
About MediWound
MediWound Ltd. is an Israeli biotechnology company that develops topical enzymatic treatments for tissue repair. Its products are designed to remove damaged tissue and support care for patients with burns and chronic wounds. The company’s lead product, NexoBrid, is a bromelain-based treatment used to remove dead tissue from deep thermal burns. It has received regulatory approvals in the United States and other markets. In the United States, MediWound works with Vericel to commercialize the product.
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.
